Pilot Study AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children
Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients
⁃ Adults: \> 15 years and 6 months
⁃ Pediatrics: ≥ 3 years and ≤ 15 years and 6 months
⁃ Known SS or Sβ0 phenotypes
‣ 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration
• Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder
‣ 4-Blood sample planned as part of medical care